Using MASL to Combat Oral Cancer

  • End date
    Dec 31, 2024
  • participants needed
  • sponsor
    Rowan University
Updated on 9 May 2022
oral cancer


This project will evaluate the expression of a receptor called podoplanin (PDPN) in cells from oral cancers and precancerous lesions. We will also determine how sensitive oral cancer cells are to a potential drug called Maackia amurensis seed lectin (MASL).

Condition Squamous Cell Carcinoma of Head and Neck
Treatment Placebo, MASL
Clinical Study IdentifierNCT04188665
SponsorRowan University
Last Modified on9 May 2022


Yes No Not Sure

Inclusion Criteria

Males and females of at least 18 years of age who are able to give consent
Smokers and non-smokers
Persons with white or red spots and/or lesions suspected or found to be oral cancer or precancer on the inner surface of the mouth
Oral lesions will be classified as OSCC or leukoplakia including, proliferative verrucous leukoplakia, conventional erythroplakia, suspect oral papillomas, or oral lichen planus. Only patients with such histologically confirmed diagnoses will be considered for inclusion
patients will be considered for inclusion at any stage of disease progression
Patients will be considered for inclusion if a subsequent biopsy or surgical resection are planned as part of their best care treatment
Patients will have an Eastern Cooperative Oncology Group performance status of 0 or 1
Patients will display normal organ function as evidenced by standard laboratory blood tests including liver enzymes and creatine
Patients will not present evidence of comorbidities including ongoing or active infection, unstable illness, or medical conditions

Exclusion Criteria

Patients with cognitive impairments and cannot consent for themselves
Patients with language/hearing impairments
Use of a topical steroid product within the last 2 weeks
Pregnant women (to avoid any potential risk to the fetus) to be confirmed by standard blood or urine tests according to best care practice
Patients who are breastfeeding
Abstinence or use of adequate contraception will be required for women of childbearing potential and men of reproductive potential
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note